肝功能对尿路阿尔茨海默症相关神经线程蛋白的影响:在中国老年人群中进行的实验室横截面研究
He Jin1,2, Qiu Yang2, Guodong Chen2
1Central Laboratory, Beijing Geriatric Medical Research Center, Key Laboratory for Neurodegenerative Disease of Ministry of Education, Xuanwu Hospital, Capital Medical University, Beijing, China.
Journal of Alzheimer's disease : JAD
|July 5, 2024
概括
尿中与阿尔茨海默氏症相关的神经线蛋白 (AD7c-NTP) 水平受到肝功能的影响. 关键指标如白蛋白/血球蛋白比率,AST,BUN和尿酸与AD7c-NTP显著相关,影响其临床使用.
科学领域:
- 生物化学 生物化学
- 老年学是指老年学的学科.
- 神经学 神经学
背景情况:
- 尿中与阿尔茨海默氏症相关的神经线蛋白 (AD7c-NTP) 作为阿尔茨海默氏症 (AD) 的早期诊断生物标志物.
- 肝功能对尿道AD7c-NTP水平的影响在很大程度上仍未得到研究.
研究的目的:
- 研究老年人肝功能指标与尿道AD7c-NTP水平之间的关系.
- 确定肝功能是否影响AD7c-NTP作为阿尔茨海默病生物标志物的可靠性.
主要方法:
- 招募了453名年龄在60-100岁之间的参与者.
- 使用自动化化学分析仪测量血清肝功能指标.
- 通过酶相关免疫吸收试验量化尿中AD7c-NTP水平.
主要成果:
- 斯皮尔曼的相关性揭示了尿道AD7c-NTP与白蛋白,白蛋白/血球蛋白比率,胆化酶,总二氧化碳和膜过率之间的显著负相关性.
- 在尿道AD7c-NTP和血球蛋白,AST,BUN,肌素,尿酸和cystatin C之间观察到积极的相关性.
- 拉索和多重线性回归确定了白蛋白/血球蛋白比率,AST,BUN和尿酸作为尿液AD7c-NTP水平的显著预测因素.
结论:
- 肝功能指标显著影响尿道AD7c-NTP水平.
- 这些发现需要在诊断阿尔茨海默病的临床环境中解释尿中AD7c-NTP水平时考虑肝功能.
相关概念视频
Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
Alzheimer's Disease: Treatment
177
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
177


